NCT04730778View on ClinicalTrials.gov

Predictive Value of CHA2DS2VASC Score for Contrast-induced Nephropathy After Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction Patients

CompletedOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

December 15, 2022

Study Completion Date

April 15, 2023

Conditions
Acute ST Segment Elevation Myocardial Infarction
Interventions
DIAGNOSTIC_TEST

serum creatinine and estimated glomerular filtration rate, on daily basis

Assess establishing criteria of CIN through a week after primary PCI

Trial Locations (1)

11562

Kasralainy hospital, faculty of medicine, Cairo university, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT04730778 - Predictive Value of CHA2DS2VASC Score for Contrast-induced Nephropathy After Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction Patients | Biotech Hunter | Biotech Hunter